Qi Ai Wen Chen Yonggui Li Guoqing Li
10.3389/fimmu.2022.840916
Front Immunol
2022 Jun 3;13:840916.
acute erosive hemorrhagic gastritis immune checkpoint inhibitor immune-related adverse event sintilimab upper gastrointestinal tract irae
CC BY
https://pubmed.ncbi.nlm.nih.gov/35720298/
Antineoplastic Agents, Immunological / therapeutic use Carcinoma, Non-Small-Cell Lung / drug therapy Gastritis / chemically induced Gastritis / diagnosis Gastritis / drug therapy Lung Neoplasms / drug therapy Upper Gastrointestinal Tract / pathology
Antineoplastic Agents, Immunological / therapeutic use Carcinoma, Non-Small-Cell Lung / drug therapy Gastritis / chemically induced Gastritis / diagnosis Gastritis / drug therapy Lung Neoplasms / drug therapy Upper Gastrointestinal Tract / pathology Case Reports Antibodies, Monoclonal, Humanized Gastrointestinal Hemorrhage / chemically induced Gastrointestinal Hemorrhage / diagnosis Humans Male Middle Aged Antibodies, Monoclonal, Humanized Antineoplastic Agents, Immunological sintilimab
PMC9204206
35720298
Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis
2022